Many projects have been done with out M-Det-56 proof-of-concept platform. Here we present some of these results to demonstrate the power of M-DET approach for differential diagnosis of breast and ovarian cancers.

Obviously, the more fragments we test to find those few that will be the best for a specific task, the better will be the results. Here we show (image in the next section) the difference between Proof-of-Concept M-Det-56 and M-Det-244k platforms.

Imagine how much better will be the results for your project! 

An example of Proof-of-Concept results for differential diagnosis of breast and ovarian cancers (here the Proof-of Concept M-DET-56 was used to select informative fragments):

Breast cancer 

                                       Sensitivity   Specificity

Healthy vs. DCIS                80%               88%

Healthy vs. IDC                   87%               85%

IDC vs. DCIS                        87%               76%

Increasing the number of tested sites from 56 to 244,000 allows us to:

• Select better components for the composite biomarker;
• Increase the sensitivity  and the specificity of the biomarker
• Improve accuracy and reduce errors
• Reduce false-positives and false negatives to negligible level
• Make diagnosis, prediction of response and its monitoring very precise
• Make a step towards truly Personalized Medicine